Search research articles
Contact Us
Filters
Showing results (101-110 of 117) with videos related to
Page
of 12
Sort By:
European Journal of Psychotraumatology
|
May 6, 2025
The International Trauma Interview (ITI): development of a semi-structured diagnostic interview and evaluation in a UK sample
Neil P Roberts, Philip Hyland, Robert Fox, et al.
Arthritis Care & Research
|
July 9, 2016
Treatment Guidelines for Rheumatologic Manifestations of Sjögren's Syndrome: Use of Biologic Agents, Management of Fatigue, and Inflammatory Musculoskeletal Pain
Steven E Carsons, Frederick B Vivino, Ann Parke, et al.
Neurology
|
December 17, 2020
Siponimod and Cognition in Secondary Progressive Multiple Sclerosis: EXPAND Secondary Analyses
Ralph H B Benedict, Davorka Tomic, Bruce A Cree, et al.
Journal of Pharmacokinetics and Pharmacodynamics
|
July 27, 2018
Data standards for model-informed drug development: an ISoP initiative
Andrijana Radivojevic, Brian Corrigan, Nicholas Downie, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
June 19, 2015
Comparison of 2 Carmustine-Containing Regimens in the Rituximab Era: Excellent Outcomes Even in Poor-Risk Patients
Paolo F Caimi, Basem M William, Carlos H Silva Rondon, et al.
Revista Brasileira De Hematologia E Hemoterapia
|
November 20, 2016
Outcomes of allogeneic hematopoietic stem cell transplantation for lymphomas: a single-institution experience
Mira Romany Massoud, Paolo Fabrizio Caimi, Nicole Ferrari, et al.
Lancet (London, England)
|
December 3, 2021
Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial
Simon J Bowman, Robert Fox, Thomas Dörner, et al.
Arthritis & Rheumatology (Hoboken, N.J.)
|
November 18, 2024
Safety and Efficacy of Ianalumab in Patients With Sjögren's Disease: 52-Week Results From a Randomized, Placebo-Controlled, Phase 2b Dose-Ranging Study
Thomas Dörner, Simon J Bowman, Robert Fox, et al.
Arthritis & Rheumatology (Hoboken, N.J.)
|
November 3, 2024
Recommendations for Aligned Nomenclature of Peripheral Nervous System Disorders Across Rheumatology and Neurology
Ghaith Noaiseh, Anahita Deboo, Jennifer K King, et al.
Arthritis Care & Research
|
December 2, 2025
Clinical Practice Guideline for Evaluation and Management of Peripheral Nervous System Manifestations in Sjögren's Disease
Anahita Deboo, Robert Fox, Katherine M Hammitt, et al.
Page
of 12
Search research articles
Search
Showing results (101-110 of 117) with videos related to
Sort By:
Page
of 12
European Journal of Psychotraumatology
|
May 6, 2025
The International Trauma Interview (ITI): development of a semi-structured diagnostic interview and evaluation in a UK sample
Neil P Roberts, Philip Hyland, Robert Fox, et al.
Arthritis Care & Research
|
July 9, 2016
Treatment Guidelines for Rheumatologic Manifestations of Sjögren's Syndrome: Use of Biologic Agents, Management of Fatigue, and Inflammatory Musculoskeletal Pain
Steven E Carsons, Frederick B Vivino, Ann Parke, et al.
Neurology
|
December 17, 2020
Siponimod and Cognition in Secondary Progressive Multiple Sclerosis: EXPAND Secondary Analyses
Ralph H B Benedict, Davorka Tomic, Bruce A Cree, et al.
Journal of Pharmacokinetics and Pharmacodynamics
|
July 27, 2018
Data standards for model-informed drug development: an ISoP initiative
Andrijana Radivojevic, Brian Corrigan, Nicholas Downie, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
June 19, 2015
Comparison of 2 Carmustine-Containing Regimens in the Rituximab Era: Excellent Outcomes Even in Poor-Risk Patients
Paolo F Caimi, Basem M William, Carlos H Silva Rondon, et al.
Revista Brasileira De Hematologia E Hemoterapia
|
November 20, 2016
Outcomes of allogeneic hematopoietic stem cell transplantation for lymphomas: a single-institution experience
Mira Romany Massoud, Paolo Fabrizio Caimi, Nicole Ferrari, et al.
Lancet (London, England)
|
December 3, 2021
Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial
Simon J Bowman, Robert Fox, Thomas Dörner, et al.
Arthritis & Rheumatology (Hoboken, N.J.)
|
November 18, 2024
Safety and Efficacy of Ianalumab in Patients With Sjögren's Disease: 52-Week Results From a Randomized, Placebo-Controlled, Phase 2b Dose-Ranging Study
Thomas Dörner, Simon J Bowman, Robert Fox, et al.
Arthritis & Rheumatology (Hoboken, N.J.)
|
November 3, 2024
Recommendations for Aligned Nomenclature of Peripheral Nervous System Disorders Across Rheumatology and Neurology
Ghaith Noaiseh, Anahita Deboo, Jennifer K King, et al.
Arthritis Care & Research
|
December 2, 2025
Clinical Practice Guideline for Evaluation and Management of Peripheral Nervous System Manifestations in Sjögren's Disease
Anahita Deboo, Robert Fox, Katherine M Hammitt, et al.
Page
of 12